-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 31, 2000
SEROLOGICALS CORPORATION
------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-26126 58-2152225
------------------------------------------------------------------------------
(State of other (IRS Employer (Commission file number)
jurisdiction) Identification No.)
780 Park North Blvd.
Suite 110
Atlanta, Georgia 30021
------------------------------------------------------------------------------
(Address of Principal executive offices) (Zip code)
Registrant's telephone number, including area code: (404) 296-5595
(Former name or former address, if changed since last report)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Item 5. Other Events
On May 31, 2000, Serologicals Corporation issued a press release, the
text of which is attached hereto as Exhibit 99.1 and is incorporated herein
by reference, announcing that it has signed a definitive agreement to sell
substantially all of the assets of its Seramed, Inc. subsidiary.
Item 7. Financial Statements and Exhibits
a) Financial statements of businesses acquired:
Not applicable
b) Pro forma financial information:
Not applicable
c) Exhibits
Exhibit No. Description
99.1 Press Release dated May 31, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Serologicals Corporation
(Registrant)
June 1, 2000 By: /s/ Peter J. Pizzo, III
-------------------------------
Peter J. Pizzo, III
Vice President, Finance and
Chief Financial Officer
